These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 3677127)

  • 1. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.
    Ludwig H; Linkesch W; Gisslinger H; Fritz E; Sinzinger H; Radaszkiewicz T; Chott A; Flener R; Micksche M
    Cancer Immunol Immunother; 1987; 25(3):266-73. PubMed ID: 3677127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
    Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
    Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.
    Gisslinger H; Ludwig H; Linkesch W; Chott A; Fritz E; Radaszkiewicz T
    Lancet; 1989 Mar; 1(8639):634-7. PubMed ID: 2564458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
    Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
    Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
    Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.
    Chott A; Gisslinger H; Thiele J; Fritz E; Linkesch W; Radaszkiewicz T; Ludwig H
    Br J Haematol; 1990 Jan; 74(1):10-6. PubMed ID: 2310690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.
    Lazzarino M; Vitale A; Morra E; Gagliardi A; Bernasconi P; Torromeo C; Inverardi D; Burgio V; Castello A; Bernasconi C
    Br J Haematol; 1989 Jun; 72(2):173-7. PubMed ID: 2757963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
    Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman JU
    Am J Med; 1989 May; 86(5):554-8. PubMed ID: 2712063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes].
    Petit J; Callís M; Domingo Albós A; Fernández de Sevilla A; Besses C; Martí JM
    Med Clin (Barc); 1993 Nov; 101(16):601-3. PubMed ID: 8271861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
    Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
    Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia.
    Thiele J; Schneider G; Hoeppner B; Wienhold S; Zankovich R; Fischer R
    Virchows Arch A Pathol Anat Histopathol; 1988; 413(5):407-17. PubMed ID: 3140482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states.
    Cashell AW; Buss DH
    Ann Hematol; 1992 Jun; 64(6):273-6. PubMed ID: 1637881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
    Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
    Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis.
    Yataganas X; Meletis J; Plata E; Viniou N; Deligiannis F; Tsekoura C; Voscaridou E; Boussiotis V; Rombos J; Vayopoulos G
    Eur J Cancer; 1991; 27 Suppl 4():S69-71. PubMed ID: 1799484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon in essential thrombocythaemia.
    Gisslinger H; Chott A; Scheithauer W; Gilly B; Linkesch W; Ludwig H
    Br J Haematol; 1991 Oct; 79 Suppl 1():42-7. PubMed ID: 1931708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b.
    Seewann HL; Zikulnig R; Gallhofer G; Schmid C
    Eur J Cancer; 1991; 27 Suppl 4():S58-62; discussion S62-3. PubMed ID: 1799482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia.
    Talpaz M; Mavligit G; Keating M; Walters RS; Gutterman JU
    Ann Intern Med; 1983 Dec; 99(6):789-92. PubMed ID: 6580836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
    Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
    Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.